Novo Nordisk's healthcare solutions, while praised for their effectiveness in treating obesity, face criticism over high costs and disparities in access for Americans.
Novo Nordisk CEO Lars Fruergaard Jørgensen defended the company's high prices, emphasizing that more work is needed on the complex U.S. healthcare system.
Senator Bernie Sanders has called for Novo Nordisk to lower their drug prices to aid the American public in tackling the obesity epidemic.
The demand for Novo's GLP-1 drugs for weight loss has surged, leading to a significant increase in the company's market value and sales.
Collection
[
|
...
]